Data from a meta-analysis showed that neoadjuvant chemotherapy by PD-1 and PD-L1 ICIs may be well tolerated and effective for HNSCC patients [223], which encourages further research. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.